linjc16/ctgov huggingface dataset:
The Effect of Sildenafil on Sleep-Disordered Breathing in Obese Patients With Sexual Dysfunction

Study Overview
=================
Brief Summary
-----------------
Sildenafil has been shown to aggravate sleep-disordered breathing in patients with severe obstructive sleep apnea. The aim of the present study is to examine the frequency of sleep-disordered breathing in obese patients who are candidates for treatment with sildenafil for sexual dysfunction. In addition we wish to assess the effect of sildenafil on sleep-disordered breathing.

Official Title
-----------------
The Effect of Sildenafil on Sleep-Disordered Breathing in Obese Patients With Sexual Dysfunction

Conditions
-----------------
Sildenafil, Sleep Apnea, Sexual Dysfunction, Obesity

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age - 40-65 years BMI equal to or over 30 Exclusion Criteria: A known cardiorespiratory, liver or kidney disease Treatment with nitrates or alfa blockers Performed polysomnography in the past

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Sildenafil<br>Treated with 50 mg of Sildenafil at night | |
| Placebo<br>Treated with placebo at night | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| apnea hypopnea index after sildenafil vs. placebo |  | Hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sleep parameters (latency, efficiency etc) following sildenafil vs. placebo |  | hours |
Professional and Ethical Challenges of Social Media Usage in Providing Healthcare Services During the Period of 19 Covid Pandemics;

Study Overview
=================
Brief Summary
-----------------
integrating social media into medicine has obvious potential to improve patient care and trust in the profession, in part by meeting patients where they are, i.e., online, at the same time carries a greater risk in terms of legal, ethical, and professional aspects. Therefore, physicians and medical students using social media should pay attention to the ethical sensitivity in their relationships with patients .it also raises a number of ethical issues including protecting patient and physician privacy; setting appropriate online boundaries; and delineating personal and professional identities among others during covid 19 pandemics

Official Title
-----------------
Professional and Ethical Challenges of Social Media Usage in Providing Healthcare Services; During the Period of 19 Covid Pandemics

Conditions
-----------------
Evaluating the Effect of Social Media Usage in Providing Healthcare Services During the Period of 19 Covid Pandemics

Intervention / Treatment
-----------------
* Other: quesionnair


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: adult aged 18 years to 60 years medical personel graduated from egyptian faculty of medicine. non medical personel live in egypt Exclusion Criteria: personel less than 18 years old . medical personel not graduated from egyptian faculty of medicine. non medical personel live outside egypt

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| medical personel<br> | Other: quesionnair<br>* questionnair about Emerging Legal and Ehical Disputes Over Patient Confidentiality<br>|
| non medical personel<br> | Other: quesionnair<br>* questionnair about Emerging Legal and Ehical Disputes Over Patient Confidentiality<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| to evaluate the effect of social media usage in medical practice during covid 19 epidemic | to evaluate the effect of social media usage in medical practice during covid 19 epidemic | 3 months |
Use of Electroconvulsive Therapy (ECT) in Chronic, Severe, Treatment Resistant Posttraumatic Stress Disorder

Study Overview
=================
Brief Summary
-----------------
Post Traumatic Stress Disorder is a chronic debilitating illness and few treatment options have demonstrated effectiveness. The study will look at the use of electroconvulsive therapy for the treatment of Post Traumatic Stress disorder in patients who have not responded to multiple antidepressants or cognitive behavioral therapy.

Official Title
-----------------
Efficacy of ECT in Chronic, Severe, Antidepressant- And CBT-Refractory Posttraumatic Stress Disorder: An Open, Prospective Study

Conditions
-----------------
Posttraumatic Stress Disorder

Intervention / Treatment
-----------------
* Procedure: Electroconvulsive Therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of PTSD Treatment resistance to 4 different antidepressants from 3 different classes Treatment resistance to CBT Severe PTSD Exclusion Criteria: Significant substance abuse Pregnancy History of Traumatic Brain Injury Unstable comorbid medical illness Organic brain syndrome

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Electroconvulsive Therapy|ECT was administered using the MECTA-SR1 apparatus. The current amplitude was 800 mA, pulse width was 1.5 ms, and pulse frequency was 50 Hz. Stimulus duration was increased as required to elicit an adequate seizure, defined as at least 25 s with EEG monitoring. The ECT course was fixed, and comprised 6 treatments administered with bitemporal electrode placement at a twice-weekly frequency|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinician-Administered Posttraumatic Stress Disorder Scale (CAPS) SCORE |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Montgomery-Asberg Depression Rating Scale score |  | baseline, 48 hrs post 3rd, 6th ECT | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
posttraumatic stress disorder, electroconvulsive therapy, medication refractoriness
Preconditioning With Hyperbaric Oxygen in Cardiovascular Surgery

Study Overview
=================
Brief Summary
-----------------
Animal studies have shown that preconditioning with hyperbaric oxygen can induce central nervous system and heart ischemic tolerance. This study was designed to determine the protective effect of hyperbaric oxygen preconditioning on brain and myocardium ischemia-reperfusion injury during coronary artery bypass graft surgery.

Detailed Description
-----------------
60 patients scheduled to undergo coronary revascularization were recruited for this trial. Exclusion criteria included Emergency operation, age older than 80 years, learning difficulty, previous cerebrovascular disease, visual or hearing impairment, history of pneumothorax, Claustrophobia, middle ear disease, EF < 35%. Patients were randomized either to the control group or hyperbaric oxygen group. The laboratory analysis of markers included S100B, NSE and troponin I. The assessment of cognitive dysfunction was performed 5 days before surgery and 7 days after surgery and haemodynamic measurements, length of stay in ICU, length of stay in hospital post-operation were recorded.

Official Title
-----------------
Phase 1 Study of Protective Effect of Hyperbaric Oxygen Preconditioning on Brain and Myocardium Injury During CABG Surgery

Conditions
-----------------
Brain Injury, Myocardial Injury

Intervention / Treatment
-----------------
* Device: Hyperbaric oxygen pretreatment (GR2200)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients scheduled to undergo coronary revascularization surgery. Exclusion Criteria: Emergency operation Age older than 80 years Learning difficulty Previous cerebrovascular disease Visual or hearing impairment History of pneumothorax, claustrophobia, middle ear disease, EF < 35%

Ages Eligible for Study
-----------------
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: HBO<br> | Device: Hyperbaric oxygen pretreatment (GR2200)<br>* 2 hours/day,5 days before surgery<br>* Other names: GR2200;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Post operative cognitive dysfunction |  | 5 days before surgery and 7 days after surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| S100B protein,NSE and Troponin I |  | Within the first 3 days after surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
CABG, hyperbaric oxygen, preconditioning, S100B, NSE, Troponin I, CABG surgery, neuroprotection
Congenital Malformations and Maternal Use of Anti-hypertensive Medication in the United Kingdom

Study Overview
=================
Brief Summary
-----------------
Assess Fetal Mortality and Malformations in Women treated with antihypertensive medication during preganancy. Mother - Child pairs will be analysed in a cohort selected from the UK in the CPRD database. Years covered are 1997 to 2014. Aim is to assess the risk of Antihypertensive treatment in women.

Detailed Description
-----------------
Women with chronic hypertension are at risk of experiencing severe complications such as adverse effects of fetal growth, survival, and renal function during pregnancy. General recommendations advocate the treatment of high blood pressure during pregnancy to decrease these risks to the mother and child, with extreme caution. Many studies assessing the risk of congenital malformations in infants whose mothers were treated with anti-hypertensive medication have been inconclusive, in part due to the variability of the original data sources and possibly the robustness of the analyses.2 Studies regarding this health issue have been unable to stratify anti-hypertensive medications sufficiently to truly assess the risk per drug class, Angiotensin II Receptor Antagonists/Blockers (ARBs) and Angiotensin-converting-enzyme inhibitor (ACE inhibitor) in particular.We will attempt to assess the prescription rate of ARBs and ACE inhibitors among women with very high blood pressure in the United Kingdom (UK) and estimate the risk of serious foetal outcomes in women treated with ARBs and/or ACEs and who may also have the following co-morbid conditions: Diabetes Types I or II, Diabetic Nephropathy, and Congestive Heart Failure.

Official Title
-----------------
Congenital Malformations and Maternal Use of Anti-hypertensive Medication in the United Kingdom

Conditions
-----------------
Hypertension

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age and gender - Exclusion Criteria: -
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incident cases of Fetal Mortality among hypertensive women | Number of incident Fetal mortality cases among hypertensive women, study period duration is 204 months (start date 1997 to end of follow-up date 2014) | up to 17 years | 
| Incident cases of Fetal Malformation among hypertensive women | Number of incident Fetal Malformation cases among hypertensive women, study period duration is 204 months (start date 1997 to end of follow-up date 2014) | up to 17 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hypertension malformation fetal mortality
BAY12-8039, iv/Oral Pulmonary Abscess/Aspiration Pneumonia

Study Overview
=================
Brief Summary
-----------------
The purpose of this trial is to determine the efficacy and safety of Moxifloxacin in comparison to Sulbactam/Ampicillin in the treatment of pulmonary abscesses and aspiration pneumonia.

Official Title
-----------------
Prospective, Multi-center, Randomized, Non-blind Trial to Assess the Efficacy and Safety of Moxifloxacin Versus Sulbactam/Ampicillin in the Treatment of Pulmonary Abscess and Aspiration Pneumonia

Conditions
-----------------
Pneumonia, Aspiration, Lung Abscess

Intervention / Treatment
-----------------
* Drug: Avelox (Moxifloxacin, BAY12-8039)
* Drug: Sulbactam/Ampicillin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female patients aged 18 years or above The primary diagnosis is community or hospital acquired primary pulmonary abscess or aspiration pneumonia, requiring initial parenteral treatment Exclusion Criteria: Known hypersensitivity to fluoroquinolones and/or ß-lactams Patients with mechanical ventilation lasting more than 48 hours prior to enrollment, with poststenotic pneumonia, infarction pneumonia, pulmonary tuberculosis, lung abscess/pneumonia with concomitant endocarditis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Arm 1<br> | Drug: Avelox (Moxifloxacin, BAY12-8039)<br>* Moxifloxacin, 400 mg iv, od, switch after 6 doses (6 days) to 400 mg Moxifloxacin oral, od<br>|
| Active Comparator: Arm 2<br> | Drug: Sulbactam/Ampicillin<br>* Sulbactam/Ampicillin, 3 g iv, tid, switch after 18 doses (6 days) to 750 mg Sulbactam/Ampicillin oral, bid<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adverse events occuring after first application of study medication up to the test of cure visit for non-serious adverse events |  | Up to 30 days after end of treatment with study medication for serious adverse events | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical Response |  | Regulary doing i.v. treatment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pulmonary Abscess, Aspiration Pneumonia
Personalized Multi-peptide Vaccination in Combination With the TLR1/2 Ligand XS15 in Cancer Patients

Study Overview
=================
Brief Summary
-----------------
The aim of this project is to provide personalized multi-peptide vaccination in combination with the TLR1/2 ligand XS15 to individual patients with advanced solid and hematological malignancies without any approved treatment options.

Detailed Description
-----------------
Ethics: Patient treatment will be conducted according to §13 Absatz 2b, AMG.

Official Title
-----------------
Personalized Multi-peptide Vaccination in Combination With the TLR1/2 Ligand XS15 in Cancer Patients

Conditions
-----------------
Cancer

Intervention / Treatment
-----------------
* Biological: Personalized multi-peptide vaccine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Documented diagnosis of advanced malignant disease Advanced malignant disease without any available standard of care treatment option Low tumor cell burden Live expectancy > 6 month Ability to understand and voluntarily sign an informed consent form. Ability to adhere to the study visit schedule and other protocol requirements Eastern Cooperative Oncology Group (ECOG) performance status score of ≤ 2. Exclusion Criteria: Pregnant or lactating females. Treatment regimens inducing sever T cell deficiencies Treatment-related side effect > CTC grade 2 (CTCAE V5.0 Participation in any clinical study or having taken any investigational therapy, which would interfere with the studys primary and secondary end points within 2 weeks prior to vaccination Pre-existing auto-immune disease except for Hashimoto thyroiditis and mild (not requiring immunosuppressive treatment) psoriasis
Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Biological: Personalized multi-peptide vaccine|Peptide vaccine: Personalized multi-peptide vaccine cocktails consisting of 200-300µg each of 5-10 tumor-associated peptides selected individually based on the patient-individual HLA allotypes and HLA ligandome analysis of tumor cells Peptides are synthesized in the GMP-certified Wirkstoffpeptidlabor at the University of Tübingen and will be formulated at the GMP-Center of the University Hospital Tübingen. Peptides will be administered subcutaneously (s.c.) together with the TLR1/2 ligand XS15 emulsified in Montanide ISA 51 VG as adjuvant. Vaccination will take place every 6 weeks. A total of two to five vaccinations are planned. Treatment schedule: Vaccination will take place every 6 weeks. A total of two to five vaccinations are planned, depended on the induction of peptide-specific T-cell responses.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Epidemiology of Persistent Pulmonary Hypertension of the Newborn - SCOR in Lung Biology and Diseases in Infants and Children

Study Overview
=================
Brief Summary
-----------------
To conduct an epidemiologic study of persistent pulmonary hypertension of the newborn ( PPHN) infant.

Detailed Description
-----------------
BACKGROUND: The study on the epidemiology of persistent pulmonary hypertension of the newborn (PPHN) was a subproject within a Specialized Center of Research (SCOR) in Lung Biology and Diseases in Infants and Children. The SCOR and its subproject were awarded in December, 1991. Dollars were estimated at 20 percent of total center dollars. DESIGN NARRATIVE: Data from a previous study of PPHN were analyzed. The objectives were to: identify the effects of a variety of potentially adverse prenatal exposures from interview data; formulate multi-variate models of risk of PPHN to determine if smoking or use of prostaglandin inhibitors increased the risk of PPHN; explore associations of PPHN with history of illicit drug use and maternal hypoxia; examine the relationships of postnatal care and perinatal risk factors on the incidence and outcome of PPHN; test the relationships of PPHN to the biochemical presence of nicotine and drugs in neonatal urine. The study completion date listed in this record was obtained from the End Date entered in the Protocol Registration and Results System (PRS) record.

Conditions
-----------------
Lung Diseases, Cardiovascular Diseases, Defect, Congenital Heart, Heart Diseases, Persistent Fetal Circulation Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
No eligibility criteria

Ages Eligible for Study
-----------------
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Understanding the Differences in the Management of Patients With Arthritis of the Knee or Hip

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to examine cultural and clinical context factors in African-American and white veterans with knee or hip osteoarthritis with a focus on how these factors may be potentially modifiable determinants of willingness to consider joint replacement.

Detailed Description
-----------------
The study focuses on identifying potentially modifiable determinants of patients� willingness to consider joint replacement as a treatment option for osteoarthritis of the knee or hip. This line of research is informed by not only our prior work but also recent studies on health disparities and patient decision-making. Our long-term goal is the development and evaluation of interventions to target these determinants of willingness in order to eliminate ethnic disparities in joint replacement. The study findings will assist in laying the groundwork for the design of such interventions for patients with osteoarthritis.

Official Title
-----------------
Reasons for Disparities in Joint Replacement Utilization

Conditions
-----------------
Osteoarthritis, Arthritis, Degenerative, Osteoarthritis, Hip, Osteoarthritis, Knee

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Chronic, frequent knee or hip pain based on the National Health And Nutrition Examination Survey Age >50 and <80 (at least 50 but not to exceed 79 years of age) Severe or extreme knee or hip OA on the Western Ontario and McMaster Universities Osteoarthritis Index (i.e., score greater than or equal to 39) Exclusion Criteria: Prior history of knee or hip joint replacement Terminal illness (i.e., end-stage cancer, CHF, COPD, etc.) Physician-diagnosed inflammatory arthritis Dementia Prosthetic leg

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 79 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group 1<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Racial/ethnic health disparities, Attitudes, Osteoarthritis Management, Patient Perceptions